BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study
Abstract
We investigated the pharmacodynamics (PD) and pharmacokinetics (PK) of BioChaperone insulin Lispro (BCLIS), faster insulin aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes using an insulin pump. In this randomized, double-blind, three-way crossover glucose clamp study, 43 patients received a bolus dose of each insulin (0.15 U/kg) in addition to a basal rate (0.01 U/kg/h), delivered via an insulin pump. With BCLIS, the AUC-GIR,0-60 minutes (primary endpoint) was improved compared to ASP (least square means ratio, 1.63; 95% CI, 1.44-1.88; P early0.5GIRmax ) than ASP and faster-off PD (t late0.5GIRmax ) than both FIA and ASP. BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins. In patients with type 1 diabetes using an insulin pump, BCLIS better mimics prandial insulin secretion and action than ASP and shows a faster off-PD than FIA.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other investigational ultrarapid insulin analogues, such as BioChaperone Lispro and AT247, are being tested in adults with diabetes.
“Other investigational ultrarapid insulin analogues, such as BioChaperone Lispro (Adocia, Lyon, France) and AT247 (Arecor, Cambridge, UK), are being tested in adults with diabetes, 82”
From The future of type 1 diabetes therapy (2025) · cites this paper as [82]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 14 · Cited by 40
- Authors
- Heise, T., Meiffren, G., Alluis, B., Seroussi, C., Ranson, A., Arrubla, J., Correia, J., Gaudier, M., Soula, O., Soula, R., DeVries, J. H., Klein, O., & Bode, B.
- Affiliations
- Profil Institute for Metabolic Research (DE)
- Adocia (France) (FR)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Heise, Tim
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-01-17
- Volume
- 21
- Issue
- 4
- Pages
- 1066-1070
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2903866003
- Cited by
- 40
- References
- 14
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 12 · 2020: 10 · 2019: 4
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Adocia sponsored this study.
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- insulin aspart, type 1 diabetes, insulin pump therapy, insulin pump, pharmacokinetics, pharmacodynamics, glucose infusion rate
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dosage Forms, Double-Blind Method, Excipients, Female, Humans, Hypoglycemic Agents, Insulin Infusion Systems, Male, Middle Aged, Glucose Clamp Technique, Cross-Over Studies, Infusions, Subcutaneous, Insulin Aspart, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
